Atox Bio Ltd., of Ness Ziona, Israel, said it was awarded a Biomedical Advanced Research and Development Authority (BARDA) contract of up to $24 million over 4.5 years to develop AB103 to treat necrotizing soft-tissue infections (NSTIs) and, potentially, infections caused by biothreats and public health threats that end in sepsis.